Is There a Generic for Baqsimi?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Baqsimi (glucagon). The Orange Book shows its last listed patent expires September 23, 2039 and its last listed exclusivity ends March 17, 2028.

Run it in Rivvi

Map Baqsimi and your other top fills to their generics

Every strength in RxNorm, with brands that have no generic flagged.

Build the map

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Baqsimi products in the Orange Book

Baqsimi products and approved generics
Form and route	Strength	Brand status	Brand TE	Active generics	Generic TE codes
powder, nasal	3MG	Marketed (Rx)	None	0	None

NDA 210134, held by AMPHASTAR PHARMACEUTICALS INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.

Baqsimi patents

Patents listed for Baqsimi
Patent	Expires	Covers	Use code	NDA
10213487	February 16, 2036	Drug product	U-2604	210134
12370241	February 16, 2036	Drug product	U-2604	210134
10765602	September 23, 2039	Drug product	None	210134

Baqsimi exclusivity

Exclusivity listed for Baqsimi
Code	Meaning	Expires	NDA
NPP	New patient population	March 17, 2028	210134

Baqsimi NDC codes

Questions

Is there a generic for Baqsimi?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Baqsimi (glucagon). The Orange Book shows its last listed patent expires September 23, 2039 and its last listed exclusivity ends March 17, 2028.

What is the generic name for Baqsimi?

The active ingredient in Baqsimi is glucagon, per the FDA Orange Book.

When does the Baqsimi patent expire?

The last patent listed for Baqsimi in the Orange Book expires September 23, 2039. A listed patent expiry date is not a generic launch date.

What does a therapeutic equivalence code mean?

In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.